Environmental

Limited Direct Environmental Impact: Rafael Holdings operates primarily as a biotechnology holding company with no direct manufacturing or extractive operations, resulting in a relatively low direct environmental footprint compared to industrial peers.

Indirect Exposure via Subsidiaries: The company’s exposure to environmental risks is primarily indirect, through its subsidiaries’ clinical development activities, which have modest energy and resource requirements but may face scrutiny over pharmaceutical waste management.

No Formal Sustainability Reporting: There is no evidence of published sustainability or climate risk disclosures, nor any stated targets for emissions, energy use, or waste reduction, which is below best practice for sector peers.

Rafael Holdings’ environmental risk profile is moderate due to its limited operational footprint, but the absence of formal sustainability policies or disclosures is a notable gap relative to best-in-class biotech peers.

Social

Clinical Trial Ethics and Patient Safety: The company’s lead asset, Trappsol® Cyclo™, is in Phase 3 trials for a rare disease, with oversight by a Data Monitoring Committee and adherence to clinical safety protocols, reflecting industry-standard patient protections.

Workforce and Leadership Changes: Recent executive appointments and board changes, including a new COO and independent directors, suggest ongoing efforts to strengthen leadership and governance, but there is limited disclosure on workforce diversity, retention, or labor practices.

Community and Stakeholder Engagement: There is no evidence of structured community engagement, philanthropic initiatives, or stakeholder dialogue beyond regulatory compliance, which is typical for small-cap biotech firms but lags leading sector practices.

Rafael Holdings demonstrates adequate social risk management in clinical development and leadership transitions, but lacks transparency and proactive engagement on broader workforce and community issues.

Governance

Board Refreshment and Independence: The company has recently appointed new independent directors, including a former U.S. Congressman and a new Lead Independent Director, which strengthens board oversight and diversity of expertise.

Audit and Compliance Oversight: Appointment of a new Audit Committee Chair and continued focus on financial controls reflect a commitment to governance best practices, though the company remains controlled by the Jonas family, which may limit minority shareholder influence.

Capital Allocation and Financial Discipline: The company completed a $25 million rights offering and maintains a strong cash position, but persistent net losses and high R&D spending relative to revenue highlight ongoing execution risk and the need for disciplined capital management.

Rafael Holdings has made progress in board refreshment and audit oversight, but concentrated ownership and ongoing financial losses present governance challenges typical of early-stage biotech firms.

Overall Score

Rafael Holdings’ ESG profile is moderate, reflecting limited direct environmental risk, adequate social safeguards in clinical development, and recent improvements in governance. However, the absence of formal sustainability disclosures, limited workforce transparency, and ongoing financial and execution risks constrain its standing relative to best-in-class biotech peers.